MYC and mantle cell lymphoma: Besides DLBCL, other tumor types showed an association of MYC and/or OxPhos gene signatures with increased resistance to various therapies, including ibrutinib in mantle cell lymphoma, neoadjuvant therapy in triple‐negative breast cancer, and venetoclax in acute myeloid leukemia (Lee et al, 2017; Sharon et al, 2019; Zhang et al, 2019).